1. Home
  2. NHI vs AKRO Comparison

NHI vs AKRO Comparison

Compare NHI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Health Investors Inc.

NHI

National Health Investors Inc.

HOLD

Current Price

$78.42

Market Cap

3.7B

Sector

Real Estate

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.53

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHI
AKRO
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.5B
IPO Year
1991
2019

Fundamental Metrics

Financial Performance
Metric
NHI
AKRO
Price
$78.42
$54.53
Analyst Decision
Buy
Buy
Analyst Count
5
10
Target Price
$84.80
$73.56
AVG Volume (30 Days)
179.5K
1.7M
Earning Date
11-06-2025
11-07-2025
Dividend Yield
4.69%
N/A
EPS Growth
8.88
N/A
EPS
3.17
N/A
Revenue
$357,572,000.00
N/A
Revenue This Year
$5.50
N/A
Revenue Next Year
$11.38
N/A
P/E Ratio
$24.75
N/A
Revenue Growth
8.40
N/A
52 Week Low
$65.13
$21.34
52 Week High
$80.56
$58.40

Technical Indicators

Market Signals
Indicator
NHI
AKRO
Relative Strength Index (RSI) 55.21 66.54
Support Level $77.57 $54.22
Resistance Level $79.82 $54.70
Average True Range (ATR) 1.30 0.14
MACD -0.02 -0.11
Stochastic Oscillator 36.68 64.18

Price Performance

Historical Comparison
NHI
AKRO

About NHI National Health Investors Inc.

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: